Rapid Micro Biosystems (RPID) - Net/Net Netting Bugs out of our Medicines

12 months ago

White Brook Capital

"RPID: Automated pharma QC systems. Cash-rich, first-to-market, established customers. -$12M EV, 1.9x LTM rev, 20%+ growth. Margins inflecting, peak burn passed. $200M mkt cap potential in 2-3 yrs. Attractive acquisition target. Grand slam potential, but sizing caution advised due to scaling challenges."

Related Stocks